Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Liang Zhao, MD
CONTACT
Haojun Chen, MD, PhD
CONTACT
Lead
The First Affiliated Hospital of Xiamen University
68Ga-XMFH01 is a novel ACP3-targeted dual-modality imaging probe with promising potential for prostate cancer detection and intraoperative surgical guidance. In this prospective study, patients with newly diagnosed prostate cancer will undergo preoperative 68Ga-XMFH01 PET/CT for initial disease assessment. Tracer uptake in tumor lesions will be quantified using the maximum standardized uptake value (SUVmax). During surgery, fluorescence imaging will be performed to identify tumor lesions and assess surgical margin status. The concordance between fluorescence-based surgical margin assessment (positive or negative) and histopathological findings will be evaluated. Following surgery, the diagnostic accuracy of 68Ga-XMFH01 PET/CT will be assessed using histopathological findings from resected specimens as the reference standard. The feasibility and safety of this dual-modality imaging approach will also be evaluated.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted